

Matsui H, Taniguchi Y, Inoue H, Uemura K, Takeda S, <u>Takahashi R</u>	A chemical neurotoxin, MPTP induces Parkinson's disease like phenotype, movement disorders and persistent loss of dopamine neurons in medaka fish	Neurosci Res	65	263-271	2009
<u>Takahashi R</u>	Edaravone in ALS (commentary)	Exp Neurol	217	235-236	2009
Inoue H, Kondo T, Lin L, Mi S, Isacson O, <u>Takahashi R</u>	Protein Misfolding and Axonal Protection in Neurodegenerative Diseases	In Protein folding and misfolding: neurodegenerative diseases	Springer	97-109	2009
村上 学、井上治久、高橋良輔	筋萎縮性側索硬化症 (ALS) の治療戦略	ファルマシア	45	1009-1112	2009
Matsui H, Taniguchi Y, Inoue H, Kobayashi Y, Sakaki Y, Toyoda A, Uemura K, Kobayashi D, Takeda S, <u>Takahashi R</u>	Loss of PINK1 in medaka fish (<i>Oryzias latipes</i>) causes late-onset decrease in spontaneous movement	Neurosci Res	66	151-161	2010
Yamakawa K, Izumi Y, Takeuchi H, Yamamoto N, Kume T, Akaike A, <u>Takahashi R</u> , Shimohama S, Sawada H	Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells	Biochem Biophys Res Commun	391	129-134	2010
Hideyama T, Yamashita T, Suzuki T, Tsuji S, Higuchi M, Seeburg PH, <u>Takahashi R</u> , Misawa H, Kwak S.	Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2	J Neurosci	30	11917-11925	2010
Murakami G, Inoue H, Tsukita K, Asai Y, Amagai Y, Aiba K, Shimogawa H, Uesugi M, Nakatsuji N, <u>Takahashi R</u>	Chemical library screening identifies a small molecule that downregulates SOD1 transcription for drugs to treat ALS	J Biomol Screen	In press	In press	2011

田中 啓二 (東京都臨床医学総合研究所)

発表者名	論文タイトル名	発表誌名	巻/号	ページ	出版年
Ichimura Y, Kumanomidou T, Sou YS, Mizushima T, Ezaki J, Ueno T, Kominami E, Yamane T, <u>Tanaka K</u> , Komatsu M.	Structural basis for sorting mechanism of p62 in selective autophagy	J Biol Chem	283	22847-22857	2008
Saeki Y, <u>Tanaka K</u> .	Cell biology: Two hands for degradation	Nature	453	460-461	2008
Ichimura Y, Kominami E, <u>Tanaka K</u> , Komatsu M.	Selective turnover of p62/a170/Sqstm1 by autophagy	Autophagy	4	1063-1066	2008
Kimura Y, Yashiroda H, Kudo T, Koitabashi S, Murata S, Kakizuka A, <u>Tanaka K</u> .	An inhibitor of deubiquitinating enzyme regulates ubiquitin homeostasis	Cell	137	549-559	2009
Saeki Y, Toh-e A, Kudo T, Kawamura H, <u>Tanaka K</u> .	Multiple proteasome-interacting proteins assist the assembly of the yeast 19S regulatory particle	Cell	137	900-913	2009
Murata S, Yashiroda H, <u>Tanaka K</u> .	Molecular mechanisms of proteasome assembly	Nat Rev Mol Cell Biol	10	104-115	2009
<u>Tanaka K</u> .	The proteasome: Overview of structure and functions	Proc Jpn Acad Ser B Phys Biol Sci	85	12-36	2009
Yue Z, Friedman L, Komatsu M, <u>Tanaka K</u> .	The cellular pathways of neuronal autophagy and their implication in neurodegenerative diseases	Biochem Biophys Acta	1793	1496-1507	2009
Sakata E, Saeki Y, <u>Tanaka K</u> .	The proteasome's crown for destruction	Mol Cell	34	519-520	2009
Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou Y-S, Ueno I, Sakamoto A, Tong K. I, Kim M, Nishito Y, Iemura S, Natsume T, Ueno T, Kominami E, Motohashi H, <u>Tanaka K</u> , Yamamoto M.	The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1	Nat Cell Biol	12	213-223	2010

Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, Sou Y, Saiki S, Kawajiri S, Sato F, Kimura M., Komatsu M, Hattori N, <u>Tanaka K.</u>	PINK1 stabilized by depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy	J Cell Biol	189	211-221	2010
Okatsu K, Saisho K, Shimanuki M, Nakada K, Shitara H, Sou Y, Kimura M, Sato S, Hattori N, Komatsu M, <u>Tanaka K.</u> , Matsuda N.	p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria	Genes Cells	15	887-900	2010
Riley B.E, Kaiser S.E, Shaler T.A, Ng A.C.Y, Hara T, Hipp M.S, Lage K, Xavier R. J, Ryu K-Y, Taguchi K, Yamamoto M, <u>Tanaka K.</u> , Mizushima N, Komatsu M, Kopito R.R.	Ubiquitin accumulation in autophagy-deficient mice is dependent on the Nrf2-mediated stress response pathway: a potential role for protein aggregation in autophagic substrate selection	J Cell Biol	191	537-552	2010
Matsuda N, <u>Tanaka K.</u>	Does impairment of the ubiquitin-proteasome system or the autophagy-lysosome pathway predispose individuals to neurodegenerative disorders such as Parkinson's disease?	J Alzheimer's Dis	19	1-9	2010
Kimura Y, <u>Tanaka K.</u>	Regulatory mechanisms involved in the control of ubiquitin homeostasis	J Biochem	147	793-798	2010

中野 今治 (自治医科大学神経内科)

発表者名	論文タイトル名	発表誌名	巻/号	ページ	出版年
Ouyang Y, Segers K, Bouquiaux O, Wang FC, Janin N, Andris C, Shimazaki H, Sakoc K, <u>Nakano I.</u> , Takiyama Y.	Novel SACS mutation in a Belgian family with sascin-related ataxia	J Neurol Sci	264	73-76	2008
Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach T.G, Buratti E, Baralle F, Morita M, <u>Nakano I.</u> , Oda T, Tsuchiya K, Akiyama H.	Phosphorylated TDP-43 in fronto temporal lobar degeneration and amyotrophic lateral sclerosis	Ann Neurol	64	60-70	2008
Shimazaki H, Morita M, <u>Nakano I.</u>	Inverse ocular bobbing in a patient with encephalitis associated with antibodies to the N-methyl-D-aspartate receptor	Arch Neurol	65	1251	2008
Yokota O, Tsuchiya K, Terada S, Ishizu H, Uchikado H, Ikeda M, Oyanagi K, <u>Nakano I.</u> , Murayama S, Kuroda S, Akiyama H.	Basophilic inclusion body disease and neuronal intermediate filament inclusion disease: a comparative clinicopathological study	Acta Neuropathol	115	561-575	2008
Shimazaki H, Vazifehmand R, Heidari M.H, Khorram-Khorshid H.R, Saber S, Hejazi S, Aghakhani-Moghadam F, Ouyang Y, Honda J, <u>Nakano I.</u> , Takiyama Y.	A large family with spinocerebellar ataxia type 6 in Iran: A Clinical and Genetic study	Archives of Iranian Medicine	11	459-462	2008
Atsuta N, Watanabe H, Ito M, Tanaka F, Tamakoshi A, <u>Nakano I.</u> , Aoki M, Tsuji S, Yuasa T, Takano H, Hayashi H, Kuzuhara S, Sobue G, Research Committee on the Neurodegenerative Diseases of Japan	Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis	J Neurol Sci	Jan15;276	163-169	2009

Hara K, Shiga A, Fukutake T, Nozaki H, Miyashita A, Yokoseki A, Kawata H, Koyama A, Arima K, Takahashi T, Ikeda M, Shiota H, Tamura M, Shimoe Y, Hirayama M, Arisato T, Yanagawa S, Tanaka A, <u>Nakano I</u> , Ikeda S, Yoshida Y, Yamamoto T, Ikeuchi T, Kuwano R, Nishizawa M, Tsuji S, Onodera O	Association of HTRA1 Mutations and Familial Ischemic Cerebral Small-Vessel Disease	N Engl J Med	360	1729-1739	2009
Okuno T, Nakayama T, Konishi N, Michibata H, Wakimoto K, Suzuki Y, Nito S, Inaba T, <u>Nakano I</u> , Muramatsu S, Takano M, Kondo Y, Inoue N	Self-Contained Induction of Neurons from Human Embryonic Stem Cells	PLoS ONE	4	e6318	2009
Muramatsu S, Okuno T, Suzuki Y, Nakayama T, Kakiuchi T, Takino N, Iida A, Ono F, Terao K, Inoue N, <u>Nakano I</u> , Kondo Y, Tsukada H	Multitracer Assessment of Dopamine Function After Transplantation of Embryonic Stem Cell-Derived Neural Stem Cells in a Primate Model of Parkinson's Disease	SYNAPSE	63	541-548	2009
Hashimoto R, Tanaka Y, <u>Nakano I</u>	Heading Disorientation : A new test and a possible underlying mechanism	Eur Neurol	63	87-93	2010
Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, Kawakami T, Urabe M, Kume A, Sato T, Watanabe E, Ozawa K, <u>Nakano I</u>	A phase I study of aromatic L-amino acid decarboxylase gene therapy for parkinson's disease	Molecular Therapy	18	1731-35	2010
Doi, Y, Yokoyama T, Tango T, Takahashi K, Fujimoto K, <u>Nakano I</u>	Temporal trends and geographic clusters of mortality from amyotrophic lateral sclerosis in Japan, 1995-2004	J Neurol Sci	298	78-84	2010
Ishihara K, Ichikawa H, Suzuki Y, Shiota J, <u>Nakano I</u> , Kawamura M	Is lesion of Exner's area linked to progressive agraphia in amyotrophic lateral sclerosis with dementia? An autopsy case report	Behav Neurol	23	153-158	2010

糸山 泰人・青木 正志（東北大学神経内科）

発表者名	論文タイトル名	発表誌名	巻・号	ページ	出版年
Mizuno H, Warita H, <u>Aoki M</u> , <u>Itoyama Y</u>	Accumulation of chondroitin sulfate proteoglycans in the microenvironment of spinal motor neurons in amyotrophic lateral sclerosis transgenic rats	J Neurosci Res	86	2512-2523	2008
Tanaka K, Okada Y, Kanno T, Otomo A, Yanagisawa Y, Shouguchi-Miyata J, Suga E, Kohiki E, Onoe K, Osuga H, <u>Aoki M</u> , Hadano S, <u>Itoyama Y</u> , Ikeda JE	A dopamine receptor antagonist L-745,870 suppresses microglia activation in spinal cord and mitigates the progression in ALS model mice	Exp Neurol	211	378-386	2008
Dagvajantsan B, <u>Aoki M</u> , Warita H, Suzuki N, <u>Itoyama Y</u>	Up-regulation of insulin-like growth factor-II receptor in reactive astrocytes in the spinal cord of amyotrophic lateral sclerosis transgenic rats	Tohoku J Exp Med	214	303-310	2008
Takahashi Y, Seki N, Ishiura H, Mitsui J, Matsukawa T, Kishino A, Onodera O, <u>Aoki M</u> , Shimozawa N, Murayama S, <u>Itoyama Y</u> , Suzuki Y, Sobue G, Nishizawa M, Goto J, Tsuji S	Development of a high-throughput microarray-based resequencing system for neurological disorders and its application to molecular genetics of amyotrophic lateral sclerosis	Arch Neurol	65	1326-1332	2008

Sasaki S, <u>Aoki M</u> , Nagai M, Kobayashi M, <u>Itoyama Y</u>	Mitochondrial alterations in transgenic mice with an H46R mutant Cu/Zn superoxide dismutase gene	J Neuropathol Exp Neurol	68	365-373	2009
Suzuki N, <u>Aoki M</u> , Warita H, Kato M, MizunoH, Shimakura N, Akiyama T, Furuya H, Hokonohara T, Iwaki A, Togashi S, Konno H, <u>Itoyama Y</u>	ALS with FUS mutation in Japan, with early onset, rapid progress and basophilic inclusion	J Hum Genet	55	252-254	2010
Suzuki N, MizunoH, Warita H, Takeda S, <u>Itoyama Y</u> , <u>Aoki M</u>	Neuronal NOS is dislocated during muscle atrophy in amyotrophic lateral sclerosis	J Neurol Sci	291	95-101	2010
Hadano S, Otomo A, Kunita R, Suzuki-Utsunomiya K, Akatsuka A, Koike M, <u>Aoki M</u> , Uchiyama Y, <u>Itoyama Y</u> , Ikeda JE	Loss of ALS2/Alsin exacerbates motor dysfunction in a SOD1-expressing mouse ALS model by disturbing endolysosomal trafficking.	PLoS One	5	e9805	2010
Kobayashi Z, Tsuchiya K, Arai T, <u>Aoki M</u> , Hasegawa M, Ishizu H, Akiyama H, Mizusawa H	Occurrence of basophilic inclusions and FUS-immunoreactive neuronal and glial inclusions in a case of familial amyotrophic lateral sclerosis	J Neurol Sci	293	6-11	2010
Sanagi T, Yuasa S, Nakamura Y, Suzuki E, <u>Aoki M</u> , Warita H, <u>Itoyama Y</u> , Uchino S, Kohsaka S, Ohsawa K	Appearance of phagocytic microglia adjacent to motoneurons in spinal cord tissue from a presymptomatic transgenic rat model of amyotrophic lateral sclerosis	J Neurosci Res	88	2736-2746	2010
Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Yabe I, Sasaki H, <u>Aoki M</u> , Morita M, Nakano I, Kanai K, Ito S, Ishikawa K, Mizusawa H, Yamamoto T, Tsuji S, Hasegawa K, Shimohata T, Nishizawa M, Miyajima H, Kanda F, Watanabe Y, Nakashima K, Tsujino A, Yamashita T, Uchino M, Fujimoto Y, Tanaka F, Sobue G; Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group	Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial	Lancet Neurol	9	875-884	2010
Shimazawa M, Tanaka H, Ito Y, Morimoto N, Tsuruma K, Kadokura M, Tamura S, Inoue T, Yamada M, Takahashi H, Warita H, <u>Aoki M</u> , Hara H.	An inducer of VGF protects cells against ER stress-induced cell death and prolongs survival in the mutant SOD1 animal models of familial ALS	PLoS One	5	e15307	2010
<u>Aoki M</u> , Warita H, Mizuno H, Suzuki N, Yuki S, <u>Itoyama Y</u>	Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger	Brain Res	25	Epub ahead of print	2011

船越 洋 (大阪大学ウイルス学/分子再生医学)

発表者名	論文タイトル名	発表誌名	巻・号	ページ	出版年
Suzuki Y, <u>Funakoshi H</u> , Machide M, Matsumoto K, Nakamura T	Regulation of cell migration and cytokine production by HGF-like protein (HLP) / macrophage stimulating protein (MSP) in primary microglia	Biomed Res	29	77-84	2008
Akita H, Takagi N, Ishihara N, Takagi K, Murotomi K, <u>Funakoshi H</u> , Matsumoto K, Nakamura K, Takeo S	Hepatocyte growth factor improves synaptic localization of the NMDA receptor and intracellular signaling after excitotoxic injury in cultured hippocampal neurons	Exp Neurol	210	83-94	2008
北村和也、中村雅也、岩波明生、船越洋、中村敏一、岡野栄之、戸山芳昭	HGFを用いた脊髄損傷治療戦略-新たな治療法の確立へ向けて	関節外科	27	37-46	2008

Kadoyama K, <u>Funakoshi H</u> , Ohya-Shimada W, Nakamura T, Matsumoto K, Matsuyama S, Nakamura T	Disease-dependent reciprocal phosphorylation of serine and tyrosine residues of c-Met/HGF receptor contributes disease retardation of a transgenic mouse model of ALS	Neurosci Res	65	194-200	2009
Tanaka S, Miyata T, Fujita T, Kawahara E, Tachino K, <u>Funakoshi H</u> , Nakamura T	Differing responses of satellite cell activity to exercise training in rat skeletal muscle	J Phys Ther Sci	21	141-145	2009
Kanai M, Nakamura T, <u>Funakoshi H</u>	Identification and characterization of novel variants of the tryptophan 2,3-dioxygenase gene: Differential regulation in the mouse nervous system during development	Neurosci Res	64	111-117	2009
Kanai M, <u>Funakoshi H</u> , Takahashi H, Hayakawa T, Mizuno S, Matsumoto K, Nakamura T	Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice	Mol Brain	2(1), 8	1-16	2009
Hocking JC, Hehr CL, Bertolesi G, <u>Funakoshi H</u> , Nakamura T, McFarlane S	LIMK1 acts downstream of BMP signaling in developing retinal ganglion cell axons but not dendrites	Dev Biol	330	273-285	2009
船越洋、金井将昭、中村敏一	トリプトファン代謝と高次脳機能	アミノ酸研究	Vol.3, No.1	15-19	2009
Benkhoucha,M, Santiago-Raber M-L, Schneiter G, Chofflon M, <u>Funakoshi H</u> , Nakamura T, Lalive PH	Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells	Proc Natl Acad Sci USA	107	6424-6429	2010
Shang J, Deguchi K, Yamashita T, Ohta Y, Zhang H, Morimoto N, Liu N, Zhang X, Tian F, Matsuura T, <u>Funakoshi H</u> , Nakamura T, Abe K	Anti-apoptotic and anti-autophagic effects of GDNF and HGF after transient MCAO in Rats	J Neurosci Res	88	2197-2206	2010
Kanai M, <u>Funakoshi H</u> , Nakamura T.	Implication of Tryptophan 2,3-Dioxygenase and its Novel Variants in the Hippocampus and Cerebellum During the Developing and Adult Brain	International Journal of Tryptophan Research	3	141-149	2010
Ohira K, Hagihara H, Toyama K, Takao K, Kanai M, <u>Funakoshi H</u> , Nakamura T, Miyakawa T	Expression of tryptophan 2,3-dioxygenase in mature granule cells of the adult mouse dentate gyrus	Molecular Brain	3	26	2010
野間 さつき、船越洋、中村敏一	肝細胞増殖因子（HGF）	日本臨床増刊号：広範囲血液・尿検査、免疫学的検査（4）—その数値をどう読むか—	68巻 増刊号7	121-130	2010
船越 洋	神経栄養因子・再生因子による神経疾患の疾患進行・再生の分子機構の解析と適用	ブレインサイエンス・レビュー	クバプロ	95-113	2010
Shang j, Deguchi K, Ohta Y, Liu N, Zhang X, Tian F, Yamashita T, Ikeda Y, Matsuura T, <u>Funakoshi H</u> , Nakamura T, Abe K	Strong neurogenesis, angiogenesis, synaptogenesis and anti-fibrosis of hepatocyte growth factor in rats brain after transient middle cerebral artery occlusion (tMCAO)	J Neurosci Res	89	86-95	2011
<u>Funakoshi H</u> , Nakamura T	Hepatocyte growth factor (HGF): Neurotrophic functions and therapeutic implications for neuronal injury/diseases	Current Signal Transduction Therapy	in press		2011

Kadoyama K, Kadoyama K, Funakoshi H, Nakamura T, Sakaeda T.	Therapeutic Potential of Hepatocyte Growth Factor for Treating Neurological Diseases	Current Drug Therapy	in press		2011
Funakoshi H, Kanai M, Nakamura T	Modulation of tryptophan metabolism, promotion of neurogenesis and alteration of anxiety-related behavior in tryptophan 2,3-dioxygenase-deficient mice	International Journal of Tryptophan Research	in press		2011

漆谷 真 (滋賀医科大学分子神経科学研究センター)

発表者名	論文タイトル名	発表誌名	巻/号	ページ	出版年
Gros-Louis F, Kriz J, Kabashi E, McDearmid J, Millecamps S, Urushitani M, Lin L, Dion P, Zhu Q, Drapeau P, Julien J-P, Rouleau GA	Als2 mRNA splicing variants detected in KO mice rescue severe motor dysfunction phenotype in Als2 knock down zebrafish	Hum Mol Genet	17	2691-2702	2008
Urushitani M, Abou Ezzi S, Matsuo A, Tooyama I, Julien JP	The endoplasmic reticulum-Golgi pathway is a major target for translocation and aggregation of mutant superoxide dismutase linked to ALS	FASEB J	22	2476-2487	2008
漆谷 真	ALSモデルマウスの免疫療法と今後の展望	Brain and Nerve	60	643-651	2008
Gros-Louis F, Andersen PM, Dupre N, Urushitani M, Dion P, Souchon F, D'Amour M, Camu W, Meininger V, Bouchard JP, Rouleau GA, Julien JP.	Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis	Proc Natl Acad Sci U S A	106	21777-21782	2009
Sato T, Takeuchi S, Saito A, Ding W, Matsuura H, Bamba H, Hisa Y, Tooyama I, Urushitani M.	Axonal ligation induces transient nuclear exclusion of TDP-43 in brainstem motor neurons	Neuroscience	164	1565-1578	2009
漆谷 真	筋萎縮性側索硬化症に対するワクチン・抗体療法の展望	難病とケア	15	35-39	2009
Takeuchi S, Fujiwara N, Ido A, Oono M, Takeuchi Y, Tateno M, Suzuki K, Takahashi R, Tooyama I, Taniguchi N, Julien JP, Urushitani M	Induction of protective immunity by vaccination with wild-type apo SOD1 in the mutant SOD1 transgenic mice	J Neuropathol Exp Neurol	69	1044-1056	2010
Ezzi SA, Larivière R, Urushitani M, Julien JP	Neuronal overexpression of chromogranin A accelerates disease onset in a mouse model of ALS	J Neurochem	115	1102-1111	2010
Urushitani M, Sato T, Bamba H, Hisa Y, Tooyama I.	Synergistic effect between proteasome and autophagosome in the clearance of poly-ubiquitinated TDP-43	J Neurosci Res	88	784-797	2010
Zhao W, Beers DR, Henkel JS, Zhang W, Urushitani M, Julien JP, Appel SH.	Extracellular mutant SOD1 induces microglial-mediated motoneuron injury	Glia	58	231-243	2010
漆谷 真	免疫療法によるALSの分子標的治療	医学のあゆみ	235	255-260	2010
漆谷 真	TDP-43の異所性局在機構	最新医学	65	1588-1596	2010
漆谷 真	家族性ALSマウスモデルの免疫療法	実験医学増刊号	28	799-807	2010

発表者名	論文タイトル名	発表誌名	巻/号	ページ	出版年
Schwab C, Arai T, <u>Hasegawa M</u> , Yu S, McGeer PL,	Colocalization of TDP-43 and Huntingtin in inclusions of Huntington's disease	J Neurolpathol Exp Neurol	67	1159-1165	2008
Inukai Y, Nonaka T, Arai T, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle FE, Akiyama H, Hisanaga SI, <u>Hasegawa M</u> ,	Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLU-U and ALS	FEBS Lett	582	2899-2904	2008
<u>Hasegawa M</u> , Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle F, Morita M, Nakano I, Oda T, Tsuchiya K, Akiyama H,	Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis	Ann Neurol	64	60-70	2008
Yonetani M, Nonaka T, Masuda M, Inukai Y, Oikawa T, Hisanaga SI, <u>Hasegawa M</u> .	Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant	J Biol Chem	284	7940-7950	2009
Masuda M, <u>Hasegawa M</u> , Nonaka T, Oikawa T, Yonetani M, Yamaguchi Y, Kato K, Hisanaga S, Goedert M.	Inhibition of alpha-synuclein fibril assembly by small molecules: Analysis using epitope-specific antibodies	FEBS Lett	583	787-791	2009
Yamashita M, Nonaka T, Arai T, Kametani F, Buchman VL, Ninkina N, Bachurin SO, Akiyama H, Goedert M, <u>Hasegawa M</u> .	Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models	FEBS Lett	583	2419-2424	2009
Nonaka T, Kametani F, Arai T, Akiyama H, <u>Hasegawa M</u> .	Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43	Hum Mol Genet	18	3353-3364	2009
Nonaka T, <u>Hasegawa M</u> .	A Cellular Model To Monitor Proteasome Dysfunction by alpha-Synuclein	Biochemistry	48	8014-8022	2009
Kametani F, Nonaka T, Suzuki T, Arai T, Dohmae N, Akiyama H, <u>Hasegawa M</u> .	Identification of casein kinase-1 phosphorylation sites on TDP-43	Biochem Biophys Res Commun.	382	405-409	2009
Arai T, Mackenzie IR, <u>Hasegawa M</u> , Nonaka T, Niizato K, Tsuchiya K, Iritani S, Onaya M, Akiyama H,	Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies	Acta Neuropathol	117	125-136	2009
Nonaka T, Watanabe ST, Iwatsubo T, <u>Hasegawa M</u> .	Seeded aggregation and toxicity of alpha-synuclein and tau: cellular models of neurodegenerative diseases	J Biol Chem	285	34885-34898	2010
Yokota O, Davidson Y, Arai T, <u>Hasegawa M</u> , Akiyama H, Ishizu H, Terada S, Sikkink S, Pickering-Brown S, Mann DM.	Effect of topographical distribution of alpha-synuclein pathology on TDP-43 accumulation in Lewy body disease	Acta Neuropathol	583	789-801	2010
Yokota O, Davidson Y, Bigio EH, Ishizu H, Terada S, Arai T, <u>Hasegawa M</u> , Akiyama H, Sikkink S, Pickering-Brown S, Mann DM.	Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy	Acta Neuropathol	120	55-66	2010
Tamaoka A, Arai M, Itokawa M, Arai T, <u>Hasegawa M</u> , Tsuchiya K, Takuma H, Tsuji H, Ishii A, Watanabe M, Takahashi Y, Goto J, Tsuji S, Akiyama H.	TDP-43 M337V mutation in familial amyotrophic lateral sclerosis in Japan	Intern Med	49	331-334	2010
Yamaguchi Y, Masuda M, Sasakawa H, Nonaka T, Hanashima S, Hisanaga SI, Kato K, <u>Hasegawa M</u> .	Characterization of inhibitor-bound alpha-synuclein dimer: role of alpha-synuclein N-terminal region in dimerization and inhibitor binding	J Mol Biol	395	445-456	2010

山中 宏二 (理化学研究所脳科学総合研究センター)

発表者名	論文タイトル名	発表誌名	巻/号	ページ	出版年
<u>Yamanaka K</u> , Boillee S, Roberts EA, Garcia ML, McAlonis-Downes M, Miske OR, Cleveland DW, Goldstein LSB.	Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice	Proc Natl Acad Sci USA	105	7594-7599	2008
Ilieva H, <u>Yamanaka K</u> , Malkmus S, Kakinohana O, Yaksh T, Marsala M, Cleveland DW.	Mutant dynein (Loa) triggers proprioceptive axon loss that extends survival only in the SOD1 ALS model with highest motor neuron death	Proc Natl Acad Sci USA	105	12599-12604	2008
Furukawa Y, Kaneko K, <u>Yamanaka K</u> , O'Halloran, TV, Nukina N.	Complete loss of post-translational modifications triggers fibrillar aggregation of SOD1 in familial form of ALS	J Biol Chem	283	24167-24176	2008
Cleveland DW, <u>Yamanaka K</u> , Bomont P.	Gigaxonin controls vimentin organization through tubulin chaperone-independent pathway	Hum Mol Genet	18	1384-1394	2009
Lobsiger CS, Boillee S, McAlonis-Downes M, Khan AM, Feltri ML, <u>Yamanaka K</u> , & Cleveland DW.	Schwann cells expressing dismutase active mutant SOD1 unexpectedly slow disease progression in ALS mice	Proc Natl Acad Sci USA	106	4465-4470	2009
山中宏二	筋萎縮性側索硬化症とグリア細胞	Medical Science Digest	35	262-263	2009
山中宏二	ALSの今後の研究方向と可能性は	MB Medical Rehabilitation	113	13-18	2009
Furukawa Y, Kaneko K, <u>Yamanaka K</u> , Nukina N	Mutation-dependent Polymorphism of Cu, Zn-Superoxide Dismutase Aggregates in the Familial Form of Amyotrophic Lateral Sclerosis	J Biol Chem.	285	22221-22231	2010
Israelson A, Arbel N, Da Cruz S, Ilieva H, <u>Yamanaka K</u> , Shoshan-Barmatz V, Cleveland DW	Misfolded Mutant SOD1 Directly Inhibits VDAC1 Conductance in a Mouse Model of Inherited ALS	Neuron	67	575-587	2010
山中宏二, 遠藤史人	ALSの病態-非細胞自律性の神経細胞死	医学のあゆみ	235	241-245	2010
山中宏二	神経変性疾患における細胞死研究のパラダイムシフト	実験医学増刊	28	1188-1194	2010
Lasiene J, <u>Yamanaka K</u>	Glial cells in Amyotrophic Lateral Sclerosis	Neurol Res Int		in press	2011

阿部 康二 (岡山大学神経内科)

発表者名	論文タイトル名	発表誌名	巻/号	ページ	出版年
Ohta Y, Kamiya T, Nagai M, Nagata T, Morimoto N, Miyazaki K, Murakami T, Kurata T, Takehisa Y, Ikeda Y, Asoh S, Ohta S, <u>Abe K</u>	Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis	Journal of Neuroscience Research	86	3028-3037	2008
Morimoto N, Nagai M, Miyazaki K, Kurata T, Takehisa Y, Ikeda Y, Kamiya T, Okazawa H, <u>Abe K</u>	Progressive decrease in the level of YAPdeltaCs, prosurvival isoforms of YAP, in the spinal cord of transgenic mouse carrying a mutant SOD1 gene	Journal of Neuroscience Research	87	928-936	2009
Miyazaki K, Nagai M, Morimoto N, Kurata T, Takehisa Y, Ikeda Y, <u>Abe K</u>	Spinal anterior horn has the capacity to self-regenerate in amyotrophic lateral sclerosis model mice	Journal of Neuroscience Research	87	3639-3648	2009
Miyazaki K, Nagai M, Ohta Y, Morimoto N, Kurata T, Murakami T, Takehisa Y, Ikeda Y, Kamiya T, <u>Abe K</u>	Changes of Nogo-A and receptor NgR in the lumbar spinal cord of ALS model mice	Neurological Research	31	316-321	2009

Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, Suzuki H, Komure O, Matsuura S, Kobatake K, Morimoto N, <u>Abe K</u> , Suzuki N, Aoki M, Kawata A, Hirai T, Kato T, Ogasawara K, Hirano A, Takumi T, Kusaka H, Hagiwara K, Kaji R, Kawakami H	Mutations of optineurin in amyotrophic lateral sclerosis	Nature	465	223-226	2010
Morimoto N, Nagai M, Miyazaki K, Ohta Y, Kurata T, Takehisa Y, Ikeda Y, Matsuura T, Asanuma M, <u>Abe K</u>	Induction of parkinsonism-related proteins in the spinal motor neurons of transgenic mouse carrying a mutant SOD1 gene	Journal of Neuroscience Research	88	1804-1811	2010

加藤 信介 (鳥取大学脳神経病理)

発表者名	論文タイトル名	発表誌名	巻/号	ページ	出版年
<u>Koto S</u>	Amyotrophic lateral sclerosis models and human neuropathology: Similarities and differences	Acta Neuropatol	115	97-114	2008
加藤信介	ALS1の神経病理と発症機序	Clinical Neuroscience	26	319-322	2008
Tateno M, <u>Kato S</u> , Sakurai T, Nukina N, Takahashi R, Araki T	Mutant SOD1 impairs axonal transport of acetyltransferase and acetylcholine release by sequestering KAP3	Hum Mol Genet	18	942-955	2009
Sumi H, <u>Kato S</u> , Mochimaru Y, Fujimura H, Etoh M, Sakoda S.	Nuclear TAR DNA binding protein 43 expression in spinal cord neurons co-localizes with the clinical course in amyotrophic lateral sclerosis	J Neuropathol Exp Neurol	68	37-47	2009
Yoshihara D, Fujiwara N, Ookawara T, <u>Kato S</u> , Sakiyama H, Yokose S, Eguchi H, Suzuki K.	Protective role of glutathione S-transferase A4 induced in copper/zinc-superoxide dismutase knockout mice	Free Radical Biology & Medicine	47	559-567	2009
Koyama Y, Hiratuka T, Matuzaki S, Yamagishi S, <u>Kato S</u> , Katayama Y, Tohyama M,	Familial amyotrophic lateral sclerosis (FALS)-linked SOD1 mutation accelerates neuronal cell death by activating cleavage caspase-4 under ER stress in an <i>in vitro</i> model of FALS	Neurochemistry International	57	838-843	2010
Storong MJ, Hortobagry T, Okamoto K, <u>Kato S</u>	Amyotrophic lateral sclerosis, primary lateral sclerosis and spinal muscular atrophy. In: Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Dickson D (ed)	ISN Neuropath Press, Basel		in press	2011

加藤丈夫 (山形大学第三内科)

発表者名	論文タイトル名	発表誌名	巻/号	ページ	出版年
Kuwahara T, Koyama A, Koyama S, Yoshina S, Ren C-H, <u>Kato T</u> , Mitani S, Iwatsubo T	A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic <i>C. elegans</i>	Hum Mol Genet	17	2997-3009	2008
Wada M, Nagasawa H, Kurita K, Koyama S, Arawaka S, Kawanami T, Tajima K, Daimon M, <u>Kato T</u>	Cerebral small vessel disease and C-reactive protein: results of a cross-sectional study in community-based Japanese elderly	J Neurol Sci	264	43-49	2008

Wada M, Daimon M, Emi M, Iijima H, Sato H, Koyano S, Tajima K, Kawanami T, Kurita K, Hunt SC, Hopkins PN, Kubota I, Kawata S, <u>Kato T</u>	Genetic association between aldehyde dehydrogenase 2 (ALDH2) variation and high-density lipoprotein cholesterol (HDL-C) among non-drinkers in two large population samples in Japan	<i>J Atheroscler Thromb</i>	15	179-184	2008
Wada M, Nagasawa H, Iseki C, Takahashi Y, Sato H, Arawaka S, Kawanami T, Kurita K, Daimon M, <u>Kato T</u>	Cerebral small vessel disease and chronic kidney disease (CKD): results of a cross-sectional study in community-based Japanese elderly	<i>J Neurol Sci</i>	272	36-42	2008
Karube H, Sakamoto M, Arawaka S, Hara S, Sato H, Ren C-H, Goto S, Koyama S, Wada M, Kawanami T, Kurita K, <u>Kato T</u>	N-terminal region of α -synuclein is essential for the fatty acid-induced oligomerization of the molecules	<i>FEBS Lett</i>	582	3693-3700	2008
Iseki C, Kawanami T, Nagasawa H, Wada M, Koyama S, Kikuchi K, Arawaka S, Kurita K, Daimon M, Mori E, <u>Kato T</u>	Asymptomatic ventriculomegaly with features of idiopathic normal pressure hydrocephalus on MRI (AVIM) in the elderly: A prospective study in a Japanese population	<i>J Neurol Sci</i>	277	54-57	2009
Sakamoto M, Arawaka S, Hara S, Sato H, Cui C, Machiya Y, Koyama S, Wada M, Kawanami T, Kurita K, <u>Kato T</u>	Contribution of endogenous G-protein-coupled receptor kinases to Ser129 phosphorylation of α -synuclein in HEK293 cells	<i>Biochem Biophys Res Commun</i>	384	378-382	2009
Wada M, Nagasawa H, Kawanami T, Kurita K, Daimon M, Kubota I, Kayama T, <u>Kato T</u>	Cystatin C as an index of cerebral small vessel disease: results of a cross-sectional study in community-based Japanese elderly	<i>European Journal of Neurology</i>	17	383-390	2010
Arawaka S, Machiya Y, <u>Kato T</u>	Heat Shock Proteins as Suppressors of Accumulation of Toxic Prefibrillar Intermediates and Misfolded Proteins in Neurodegenerative Diseases	<i>Current Pharmaceutical Biotechnology</i>	11	158-166	2010
Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, Suzuki H, Komure O, Matsuura S, Kobatake K, Morimoto N, Abe K, Suzuki N, Aoki M, Kawata A, Hirai T, <u>Kato T</u> , Ogasawara K, Hirano A, Takumi T, Kusaka H, Hagiwara K, Kaji R, Kawakami H	Mutations of optineurin in amyotrophic lateral sclerosis	<i>Nature</i>	465	223-226	2010
Ishiguro T, Ishikawa K, Takahashi M, Obayashi M, Amino T, Sato N, Sakamoto M, Fujigasaki H, Tsuruta F, Dolmetsch R, Arai T, Sasaki H, Nagashima K, <u>Kato T</u> , Yamada M, Takahashi H, Hashizume Y, Mizusawa H	The carboxy-terminal fragment of α_{1A} calcium channel preferentially aggregates in the cytoplasm of human spinocerebellar ataxia type 6 Purkinje cells	<i>Acta Neuropathol</i>	119	447-464	2010
<u>Kato T</u> , Emi M, Sato H, Arawaka S, Wada M, Kawanami T, Katagiri T, Tsuburaya K, Toyoshima I, Tanaka F, Sobue G, Matsubara K	Segmental copy-number gain within the region of isopenentenyl diphosphate isomerase genes in sporadic amyotrophic lateral sclerosis	<i>Biochem Biophys Res Commun</i>	402	438-442	2010

Machiya Y, Hara S, Arawaka S, Fukushima S, Sato H, Sakamoto M, Koyama S, <u>Kato T</u>	Phosphorylated α -Synuclein at Ser-129 Is Targeted to the Proteasome Pathway in a Ubiquitin-independent Manner	<i>J Biol Chem</i>	285	40732-40744	2010
加藤 丈夫	孤発性ALSのゲノム解析	<i>医学のあゆみ</i>	235	215-219	2010
<u>Kato T</u> , Sato H, Emi M, Seino T, Arawaka S, Iseki C, Takahashi Y, Wada M, Kawanami T	Segmental copy number loss of SFMBT1 gene in elderly individuals with ventriculomegaly: a community-based study	<i>Intern Med</i>	50	297-303	2011

佐々木 秀直 (北海道大学神経内科)

発表者名	論文タイトル名	発表誌名	巻/号	ページ	出版年
Tsuji-Akimoto S, Yabe I, Niino M, Kikuchi S, <u>Sasaki H</u>	Cystatin C in cerebrospinal fluid as a biomarker of ALS	<i>Neurosci Lett</i>	452	52-55	2009
Otsuki M, Nakagawa Y, Mori F, Tobioka H, Yoshida H, Tatezawa Y, Tanigawa T, Takahashi I, Yabe I, <u>Sasaki H</u> , Wakabayashi K	Progressive anterior operculum syndrome due to FTLT-DTP: a clinicopathological investigation	<i>J Neurol</i>	257	1148-1153	2010
Tsuji-Akimoto S, Hamada S, Yabe I, Tamura I, Otsuki M, Kobashi S, <u>Sasaki H</u>	Writing errors as a result of frontal dysfunction in Japanese patients with amyotrophic lateral sclerosis	<i>J Neurol</i>	257	2071-2077	2010

佐古田 三郎 (刀根山病院/大阪大学神経内科)

発表者名	論文タイトル名	発表誌名	巻/号	ページ	出版年
Shinzawa K, Sumi H, Ikawa M, Matsuoka Y, Okabe M, <u>Sakoda S</u> , Tsujimoto Y.	Neuroaxonal dystrophy caused by group VIA phospholipase deficiency in mice: a model of human neurodegenerative disease	<i>J Neurosci</i>	28	2212-2220	2008
Eto M, Sumi H, Fujimura H, Yoshikawa H, <u>Sakoda S</u> .	Pioglitazone promotes peripheral nerve remyelination after crush injury through CD36 upregulation	<i>J Peripheral Nerv Sys</i>	13	242-248	2008
Nakamori M, Kimura T, Kubota T, Matsumura T, Sumi H, Fujimura H, Takahashi MP, <u>Sakoda S</u> .	Aberrantly spliced alpha-dystrobrevin alters alpha-syntrophin binding in myotonic dystrophy type 1	<i>Neurology</i>	70	677-85	2008
Moriya M., Y. Nakatsuji, K. Miyamoto, T. Okuno, M. Kinoshita, A. Kumanogoh, S. Kusunoki, <u>Sakoda S</u> .	Edaravone, a free radical scavenger, ameliorates experimental autoimmune encephalomyelitis	<i>Neurosci Letter</i>	440	323-326	2008
Sumi H, Kato S, Mochimaru Y, Fujimura H, Etoh M, <u>Sakoda S</u> .	Nuclear TAR DNA binding protein43 expression in spinal cord neurons correlates with the clinical course in amyotrophic lateral sclerosis	<i>J Neuropathol Exp Neurol</i>	68	37-47	2009
Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T, Kumanogoh A, Kajiyama K, Yoshikawa H, <u>Sakoda S</u> .	Neuromyelitis optica: Passive transfer to rats by human immunoglobulin	<i>Biochem Biophys Res Commun.</i>	4;386	623-627	2009
Okuno T, Nakatsuji Y, Moriya M, Takamatsu H, Nojima S, Takegahara N, Toyofuku T, Nakagawa Y, Kang S, Friedel RH, <u>Sakoda S</u> , Kikutani H, Kumanogoh A .	Roles of Sema4D-Plexin-B1 Interactions in the Central Nervous System for Pathogenesis of Experimental Autoimmune Encephalomyelitis	<i>Journal of Immunology</i>	1;184	1499-1506	2010

Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T, Kumanogoh A, Kajiyama K, Yoshikawa H, <u>Sakoda S</u> .	Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells	Biochem Biophys Res Commun.	26;394	205-210	2010
--	--	-----------------------------	--------	---------	------

谷口 直之 (大阪大学微生物病研究所)

発表者名	論文タイトル名	発表誌名	巻/号	ページ	出版年
Kotani N, Gu J, Isaji T, Udaka K, <u>Taniguchi N</u> , Honke K.	Biochemical visualization of cell surface molecular clustering in living cells	Proc Natl Acad Sci USA	99	1304-1310	2008
Park YS, <u>Taniguchi N</u> .	Acrolein induces inflammatory response underlying endothelial dysfunction: a risk factor for atherosclerosis	Ann NY Acad Sci	1126	185-189	2008
<u>Taniguchi N</u> .	Human disease glycomics/proteome initiative (HGPI)	Mol Cell Proteomics	7	626-627	2008
<u>Taniguchi N</u> .	From the gamma-glutamyl cycle to the glycan cycle: a road with many turns and pleasant surprises	J Biol Chem	284	34469-34478	2009
Kotani K, Koibuchi H, Yamada T, <u>Taniguchi N</u> .	The effects of lifestyle modification on a new oxidized low-density lipoprotein marker, serum amyloid A-LDL, in subjects with primary lipid disorder	Clin Chim Acta	409	67-69	2009
Takahashi M, Kuroki Y, Ohtsubo K, <u>Taniguchi N</u> .	Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins	Carbohydr Res	344	1387-1390	2009
<u>Taniguchi N</u> , Hancock W, Lubman DM, Rudd PM.	The second golden age of glycomics: from functional glycomics to clinical applications	J Proteome Res	8	425-426	2009
Kitazume S, Tachida Y, Kato M, Yamaguchi Y, Honda T, Hashimoto Y, Wada Y, Saito T, Iwata N, Saido T, <u>Taniguchi N</u> .	Brain endothelial cells produce amyloid β from amyloid precursor protein 770 and preferentially secrete the O-glycosylated form	J Biol Chem	17	40097-40103	2010
Takeuchi S, Fujiwara N, Ido A, Ono M, Takeuchi Y, Tateno M, Suzuki K, Takahashi R, Tooyama I, <u>Taniguchi N</u> , Julien JP, Urushitani M.	Induction of protective immunity by vaccination with wild-type apo SOD1 in the mutant SOD1 transgenic mice	J. Neuropathol. Exp. Neurol	69	1044-1056	2010
Akasaka-Manyo K, Manyo H, Sakurai Y, Wojczyk BS, Kozutsumi Y, Saito Y, <u>Taniguchi N</u> , Murayama S, Spitalnik SL, Endo T.	Protective effect of N-glycan bisecting GlcNAc residues on beta-amyloid production in Alzheimer's disease	Glycobiology	20	99-106	2010
Kitazume S, Imamaki R, Ogawa K, Komi Y, Futakawa S, Kojima S, Hashimoto Y, Marth JD, Paulson JC, <u>Taniguchi N</u> .	Alpha2,6-sialic acid on platelet endothelial cell adhesion molecule (PECAM) regulates its homophilic interactions and downstream antiapoptotic signaling.	J Biol Chem	285	6515-6521	2010
Takamatsu S, Antonopoulos A, Ohtsubo K, Ditto D, Chiba Y, Le DT, Morris HR, Haslam SM, Dell A, Marth JD, <u>Taniguchi N</u> .	Physiological and glycomic characterization of N-acetylglucosaminyltransferase-IVa and -IVb double deficient mice	Glycobiology	20	485-497	2010
Shirato K, Nakajima K, Korekane H, Takamatsu S, Gao C, Angata T, Ohtsubo K, <u>Taniguchi N</u> .	Hypoxic regulation of glycosylation via the N-acetylglucosamine cycle	J Clin Biochem Nutr	48	20-25	2011

野本 明男 (微生物化学研究所)

発表者名	論文タイトル名	発表誌名	巻/号	ページ	出版年
Nishimura T, Saito M, Takano T, <u>Nomoto A</u> , Kohara M, Tsukiyama-Kohara K	Comparative aspects on the role of polypyrimidine tract-binding protein in internal initiation of hepatitis C virus and poliovirus RNAs	Comparat Immunol Microbiol Infect Dis	31	435-448	2008
Kamoshita N, <u>Nomoto A</u> , RajBhandary UL	Translation initiation from the ribosomal A site or P site, depending on the conformation of RNA pseudoknot I in dicistrovirus RNAs	Mol Cell	35	181-190	2009
Ohka S, Sakai M, Bohnert S, Igarashi H, Deinhardt K, Schiavo G, <u>Nomoto A</u>	Receptor-dependent and -independent axonal retrograde transport of poliovirus in motor neurons	J Virol	83	4995-5004	2009
Goto M, Honda E, Ogura A, <u>Nomoto A</u> , Hanaki K	Colorimetric detection of loop-mediated isothermal amplification reaction by using hydroxy naphthol blue	Bio Techniques	46	167-172	2009
Tachibana T, Okazaki S, Murayama A, Naganuma A, <u>Nomoto A</u> , Kuge S	A major peroxiredoxin-induced activation of Yap1 transcription factor is mediated by reduction-sensitive disulfide bonds and reveals a low level of transcriptional activation	J Biol Chem	284	4464-4472	2009
Igarashi H, Yoshino Y, Miyazawa M, Horie H, Ohka S, <u>Nomoto A</u>	2A protease is not a prerequisite for poliovirus replication	J Virol	84	5947-5957	2010
Koike S, <u>Nomoto A</u>	Poliomyelitis	The Picornaviruses Chapter 21		339-351	2010

水澤 英洋 (東京医科歯科大学脳神経病態学)

発表者名	論文タイトル名	発表誌名	巻/号	ページ	出版年
Sasaguri H, Mitani T, Anzai M, Kubodera T, Saito Y, Yamada H, <u>Mizusawa H</u> , Yokota T.	Difference in silencing efficiency among tissues and lack of oversaturation of microRNA pathway in short hairpin RNA transgenic mice	FEBS lett	583	213-218	2009
Uchida A, Sasaguri H, Kimura N, Ono F, Sakaue F, Hirai T, Tajiri M, Kanai K, Ohkubo T, Sano T, Shibuya K, Kobayashi M, Ueno T, Sunaga F, Ikeda S, Kubodera T, Tomori M, Sakaki K, Kusano K, Enomoto M, Yokota S, Hirai Y, Yasutomi Y, Uchihara T, Kuwabara S, <u>Mizusawa H</u> , Yokota T.	Non-human primate model of ALS with cytoplasmic mislocalization of wild-type TDP-43				in submission

V. 研究成果の刊行物・別冊

TDP-43 Depletion Induces Neuronal Cell Damage through Dysregulation of Rho Family GTPases*

Received for publication, March 5, 2009, and in revised form, June 9, 2009. Published, JBC Papers in Press, June 17, 2009, DOI 10.1074/jbc.M109.012195

Yohei Iguchi[‡], Masahisa Katsuno^{‡,§}, Jun-ichi Niwa[¶], Shin-ichi Yamada[‡], Jun Sone[‡], Masahiro Waza[‡], Hiroaki Adachi[‡], Fumiaki Tanaka[‡], Koh-ichi Nagata^{||}, Nariko Arimura^{**}, Takashi Watanabe^{§,‡,‡}, Koza Kaibuchi^{‡,‡}, and Gen Sobue^{‡,1}

From the Departments of [‡]Neurology and ^{‡,‡}Cell Pharmacology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya 466-8550, [§]Institute for Advanced Research, Nagoya University, Nagoya 464-8601, [¶]Stroke Center, Aichi Medical University, Aichi 480-1195, ^{||}Department of Molecular Neurobiology, Institute for Developmental Research, Aichi Human Service Center, Aichi 480-0838, and ^{**}Tamagawa University Brain Science Institute, Tokyo 194-8610, Japan

The 43-kDa TAR DNA-binding protein (TDP-43) is known to be a major component of the ubiquitinated inclusions characteristic of amyotrophic lateral sclerosis and frontotemporal lobar degeneration with ubiquitin-positive inclusions. Although TDP-43 is a nuclear protein, it disappears from the nucleus of affected neurons and glial cells, implicating TDP-43 loss of function in the pathogenesis of neurodegeneration. Here we show that the knockdown of TDP-43 in differentiated Neuro-2a cells inhibited neurite outgrowth and induced cell death. In knockdown cells, the Rho family members RhoA, Rac1, and Cdc42 GTPases were inactivated, and membrane localization of these molecules was reduced. In addition, TDP-43 depletion significantly suppressed protein geranylgeranylation, a key regulating factor of Rho family activity and intracellular localization. In contrast, overexpression of TDP-43 mitigated the cellular damage caused by pharmacological inhibition of geranylgeranylation. Furthermore administration of geranylgeranyl pyrophosphate partially restored cell viability and neurite outgrowth in TDP-43 knockdown cells. In summary, our data suggest that TDP-43 plays a key role in the maintenance of neuronal cell morphology and survival possibly through protein geranylgeranylation of Rho family GTPases.

The 43-kDa TAR DNA-binding protein (TDP-43)² has recently been identified as a major component of the ubiquitinated inclusions characteristic of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin-positive inclusions (1, 2). Subsequently several point mutations

located in the glycine-rich domain of TDP-43 have been identified as the disease-causing mutations of familial and sporadic ALS (3–7). TDP-43 has been shown to be a fundamental component of ubiquitin-positive neuronal cytoplasmic and intranuclear inclusions as well as that of neuronal dystrophic neurites in the affected neurons or glial cells in these neurodegenerative diseases. TDP-43 is known to regulate gene transcription, exon splicing, and exon inclusion through interactions with RNA, heterogeneous nuclear ribonucleoproteins, and nuclear bodies (8–12). Recently it has been reported that TDP-43 stabilizes human low molecular weight neurofilament mRNA through direct interaction with the 3'-untranslated region (13) and that it regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression (14). However, the physiological function of TDP-43 in the central nervous system has not been fully elucidated, and it remains unclear how this protein is implicated in the pathogenesis of neurodegeneration.

The Rho family of GTPases are members of the Ras superfamily and are known for regulating actin cytoskeletal dynamics (15–18). RhoA, Rac1, and Cdc42, the most studied proteins of this family, also modulate functions such as cell movement, motility, transcription, cell growth, and cell survival (18). In neurons, RhoA, Rac1, and Cdc42 have been shown to regulate neurite outgrowth (19–21).

Although TDP-43 is localized in the nucleus of unaffected neurons, nuclear staining of this protein is significantly reduced in neurons bearing ubiquitin inclusions (1, 2, 22), suggesting that loss of TDP-43 function may play a role in neurodegeneration. In this study, we used small interfering RNA (siRNA) to investigate the effect of TDP-43 loss of function on cell death and neurite outgrowth and elucidated a novel relation between TDP-43 and the activities of RhoA, Rac1, and Cdc42.

EXPERIMENTAL PROCEDURES

siRNA Oligonucleotides and Construction of Expression Vectors—The oligonucleotide siRNA duplex was synthesized by Takara Bio (Shiga, Japan). The siRNA sequences were as follows: scrambled (control) siRNA-set1, 5'-GAAUCAGAUGCACAUGAGUTT-3'; -set2, 5'-ACGGCCUAAUCUAACAGACTT-3'; TDP-43 siRNA-set1, 5'-GAACGAUGAACCCAUUGAATT-3'; -set2, 5'-CCAAUGCUGAACCUAAGCATT-3'. Unless otherwise mentioned, set 1 siRNA was used for TDP-43 knockdown throughout the experiments.

* This work was supported by a Center-of-Excellence grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan; grants from the Ministry of Health, Labor and Welfare of Japan; a grant from the Japan Intractable Diseases Research Foundation; and the Program for Improvement of Research Environment for Young Researchers from Special Coordination Funds for Promoting Science and Technology commissioned by the Ministry of Education, Culture, Sports, Science and Technology.

¹ To whom correspondence should be addressed: Dept. of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. Fax: 81-52-7442785; E-mail: sobueg@med.nagoya-u.ac.jp.

² The abbreviations used are: TDP-43, 43-kDa TAR DNA-binding protein; ALS, amyotrophic lateral sclerosis; siRNA, small interfering RNA; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; GGPP, geranylgeranyl pyrophosphate; MVA, mevalonic acid; PI, propidium iodide; TUNEL, terminal deoxynucleotidyltransferase dUTP nick end labeling; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Dysregulation of Rho Families by TDP-43 Depletion

The pEGFP-Rac1 construct was produced as described elsewhere (23, 24). Mouse TDP-43 (GenBankTM accession number NM_145556) cDNA was amplified by PCR from mouse brain cDNA using the following primers: 5'-GTGCTTCCTCCTTG-TGCTTC-3' and 5'-CCACACTGAACAAACCAATCTG-3'. The PCR product was cloned into the pCR-BluntII-TOPO vector (Invitrogen), and the entire coding region of mouse TDP-43 was inserted in-frame into either the KpnI and XbaI sites of the pcDNA3.1/V5His vector (Invitrogen) or the KpnI and BamHI sites of the pDsRed-Monomer-Hyg-N1 vector (Clontech). An siRNA-resistant form of the TDP-43 gene was generated by changing the targeted sequence of the siRNA to 5'-GAATGA-CGAGCCAATTGAA-3' (mutated nucleotides are underlined) using the KOD-Plus-Mutagenesis kit (Toyobo, Osaka, Japan).

Cell Culture and Transfection—Neuro-2a cells (American Type Culture Collection, Manassas, VA), a line derived from mouse neuroblastoma, were maintained as described previously (25). The transfection of siRNA into Neuro-2a cells was performed using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. For the transfection of the intended plasmid and siRNA, cells were co-transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. To differentiate the Neuro-2a cells, the medium was changed to Dulbecco's modified Eagle's medium containing 2% fetal calf serum and 20 μ M retinoic acid, and cells were cultured for 24 h. For the interventional studies, the cells were incubated for 24 h with differentiation medium containing *Clostridium difficile* toxin B (Sigma-Aldrich) or for 12 h with medium containing GGTI-298 (Calbiochem). Geranylgeranyl pyrophosphate (GGPP) (Sigma-Aldrich) was added to the differentiation medium at the indicated concentration 24 h after siRNA transfection, and cells were incubated for an additional 24 h.

Quantitative Assessment of Neurite Outgrowth—Neuro-2a cells cultured in 6-well dishes were photographed using an Olympus IX71 inverted phase-contrast microscope (Olympus, Tokyo, Japan). The length of the longest neurite was measured with Image Gauge version 4.22 software (Fujifilm, Tokyo, Japan). Averages of the lengths of over 100 transfected cells were analyzed. To confirm the efficacy of siRNA transfection, BLOCK-iTTM Alexa Fluor[®] Red Fluorescent Control (Invitrogen) was co-transfected with TDP-43 siRNA or control RNA. The efficacy of plasmid transfection was ensured using DsRed (Clontech). To assess neurite outgrowth in TDP-43 knockdown cells, we performed a time course analysis starting at 24 h after the siRNA transfection when the differentiation medium was changed.

Cell Viability and Apoptosis Analysis—The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-based cell proliferation assay was carried out on the differentiated Neuro-2a cells 48 h post-transfection using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI) according to the manufacturer's instructions. Absorbance at 490 nm was measured in a multiple plate reader (PowerscanHT, Dainippon Pharmaceutical). The assays were carried out in 6 wells for each condition. To assess cell apoptosis, differentiated Neuro-2a cells were stained with Alexa Fluor 488-conjugated Annexin V

and with propidium iodide (PI) using the Vybrant Apoptosis Assay kit (Invitrogen) according to the manufacturer's instructions. TUNEL assays were performed using the APO-DIRECTTM kit (BD Biosciences). The extent of staining in 10,000 cells was monitored by FACSCaliburTM and CellQuest version 3.1.3 acquisition and analysis software (BD Biosciences) immediately after the staining.

Caspase-3/7 Assay—Neuro-2a cells were grown on black 96-well plates. The caspase-3/7 activity of differentiated Neuro-2a cells was analyzed using the Apo-ONE homogeneous caspase-3/7 assay (Promega) after 48 h of transfection or intended treatment according to the manufacturer's instructions. Fluorescence (485/528 nm) was measured in the multiple plate reader, and the assay was carried out in 6 wells for each condition.

Quantitative Real Time PCR—mRNA levels were determined by real time PCR as described before (26). Briefly total RNA from Neuro-2a cells was reverse transcribed into first strand cDNA, real time PCR was performed, and the product was detected by the iCycler system (Bio-Rad). For an internal standard control, the expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was simultaneously quantified. The following primers were used: 5'-CCGCAT-GTCAGCCAAATACAAG-3' and 5'-ACCAGAATTGGCT-CCAACAACAG-3' for TDP-43 and 5'-TGTGTCCGTCGT-GGATCTGA-3' and 5'-TTGCTGTTGAAGTCGCAG-GAG-3' for GAPDH.

Western Blot Analysis—Western blot analyses were performed as described before (27). Briefly Neuro-2a cells were lysed in Cellytic lysis buffer (Sigma-Aldrich) containing a protease inhibitor mixture (Roche Applied Science) 48 h after transfection. For subcellular fractionation, we used the Proteo-Extract Subcellular Proteome Extraction kit (Calbiochem) according to the manufacturer's instructions. Cell lysates were separated by SDS-PAGE (5–20% gradient gel) and analyzed by Western blotting with ECL Plus detection reagents (GE Healthcare). Primary antibodies used were as follows: anti-TDP-43 rabbit polyclonal antibody (1:1000; ProteinTech, Chicago, IL), anti-Rac1 mouse monoclonal antibody (1:1000; Millipore, Temecula, CA), anti-RhoA mouse monoclonal antibody (1:1000; Cytoskeleton, Denver, CO), anti-Cdc42 rabbit polyclonal antibody (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), anti-phospho-myosin phosphatase targeting subunit 1 (Thr-853) rabbit polyclonal antibody (1:500; Millipore), anti-myosin phosphatase targeting subunit 1 rabbit polyclonal antibody (1:1000; Santa Cruz Biotechnology), anti-H-Ras rabbit polyclonal antibody (1:1000; Santa Cruz Biotechnology), anti-Rab5 rabbit polyclonal antibody (1:1000; Santa Cruz Biotechnology), anti-GAPDH mouse monoclonal antibody (1:1000; BD Pharmingen) as a cytosol marker, anti-integrin β 1 rabbit polyclonal antibody (1:1000; Santa Cruz Biotechnology) as a membrane marker, anti-green fluorescent protein mouse monoclonal antibody (1:2000; Millipore), anti-Rho GDP dissociation inhibitor rabbit polyclonal antibody (1:1000; Millipore), anti-geranylgeranyltransferase-1 β mouse polyclonal antibody (1:1000; Abnova, Taipei, Taiwan), and anti-geranylgeranyl pyrophosphate synthase rabbit polyclonal antibody (1:1000; Abgent, San Diego, CA).

Dysregulation of Rho Families by TDP-43 Depletion

Rho Family GTPase Activation Analysis—To measure RhoA and Rac1/Cdc42 GTPase activities, we used the Rho binding domain (RBD) of the Rho effector protein with Rhotekin and Cdc42/Rac interactive binding (CRIB) region of the Cdc42/Rac effector protein with p21 activated kinase 1 (PAK), respectively. Pulldown assays were performed in the presence of glutathione *S*-transferase-tagged Rhotekin-RBD and PAK-CRIB protein-agarose beads (Cytoskeleton) according to the manufacturer's instructions.

Fluorescent Images of Neuro-2a Cells—Neuro-2a cells, which were transfected with EGFP-Rac1, DsRed-TDP-43, and siRNA (TDP-43 siRNA or control RNA), were fixed by 4% paraformaldehyde with 0.1% Triton X-100 for extraction of cytosol components. After washing, samples were mounted with VECTASHIELD mounting medium (Vector Laboratories, Inc., Burlingame, CA) and then photographed with a Zeiss Axio Imager M1 (Carl Zeiss AG).

Assay of Protein Geranylgeranylation—Neuro-2a cells were transfected with siRNA on 10-cm² dishes. Twenty-four hours after the transfection, 20 μM lovastatin (Sigma) was added to the culture medium. Twenty-four hours after the addition of lovastatin, the cells were labeled by adding fresh culture medium containing 6.25 μCi/ml [¹⁴C]mevalonolactone (50–62 mCi/mmol) (GE Healthcare) and 20 μM lovastatin. Nineteen hours after labeling, the cells were harvested, and Rac1 was immunoprecipitated by incubating with 4 mg of anti-RhoA mouse monoclonal antibody (Santa Cruz Biotechnology) or anti-Rac1 mouse monoclonal antibody (Millipore) for 24 h followed by adding 20 μl of protein G-Sepharose (GE Healthcare). Immunoprecipitated proteins were separated by electrophoresis on a polyacrylamide-SDS gel. The ¹⁴C-labeled gels were fixed and soaked in Amplify Fluorographic Reagent (GE Healthcare) for 30 min. The gels were dried, and labeled proteins were visualized on a Typhoon 9410 Workstation (GE Healthcare) after exposure to a Storage Phosphor Screen (GE Healthcare) for 72 h. We validated this experiment using 20 μM GGTI-298.

Statistical Analysis—Statistical differences (not including neurite length data) were analyzed by analysis of variance and Bonferroni post hoc analyses for three or more group comparisons and the unpaired Student's *t* test for two-group comparisons. Neurite length differences were analyzed using the Mann-Whitney *U* test (SPSS version 15.0, SPSS Inc., Chicago, IL). Two-tailed *p* < 0.05 was regarded as statistically significant.

RESULTS

TDP-43 Depletion Induces Cell Death and Inhibits Neurite Outgrowth—To analyze the effect of TDP-43 depletion, two sets of siRNA oligonucleotides were transfected into Neuro-2a cells. The efficiency of TDP-43 siRNA transfection was confirmed by Western blotting and quantitative real time RT-PCR (Fig. 1, *A* and *B*). To assess cell viability, we carried out an MTS-based cell proliferation assay in differentiated Neuro-2a cells after 48 h of siRNA transfection. The viability of knockdown cells was significantly decreased by both sets of siRNA compared with each control (Fig. 1*C*). To exclude the possibility of an off-target effect, a plasmid carrying an siRNA-resistant form of TDP-43 was co-transfected together with set 1 siRNA.




FIGURE 1. Effects of endogenous TDP-43 depletion on cell viability. *A*, anti-TDP-43 Western blot of Neuro-2a cells transfected with siRNAs. *B*, the mRNA expression levels of TDP-43 measured by real time RT-PCR. Data are shown as the ratio of the mRNA level of TDP-43 to that of GAPDH. *C*, the viability of Neuro-2a cells quantified by the MTS-based cell proliferation assays. TDP-43 depletion significantly reduced cell viability. *D*, a rescue experiment using the MTS assay. Mock plasmid and an siRNA-resistant form of TDP-43 (*Mut-TDP-43*) were co-transfected into Neuro-2a cells together with TDP-43 siRNA or control RNA. *Mut-TDP-43* prevented the reduction of cell viability. *E*, Western blot of the cells transfected with mock plasmid or *Mut-TDP-43*. Error bars indicate S.D. *N.S.*, not significant.

As a result, the siRNA-resistant form of TDP-43 prevented the reduction of cell viability (Fig. 1*D*). The apoptotic process was quantified with Annexin V/PI staining and TUNEL labeling. The knockdown of TDP-43 significantly increased the number of PI-positive cells (Fig. 2*A*). However, the number of cells positive for Annexin V or TUNEL was not altered (Fig. 2, *B* and *C*). In the caspase-3/7 assay, there was no significant difference between knockdown and control cells (Fig. 2*D*). To clarify the effects of TDP-43 depletion on cellular morphology, we performed a time course experiment measuring the average length of neurites. Neurites of control cells extended over the course of 48 h, but neurite outgrowth was significantly inhibited in TDP-43-depleted cells (Fig. 2*E*).

Dysregulation of Rho Families by TDP-43 Depletion




FIGURE 2. Apoptosis analyses and quantitative assessment of neurite outgrowth in TDP-43-depleted Neuro-2a cells. *A, B, and C*, the number of the cells positive for PI, Annexin V, and TUNEL staining. We counted 10,000 cells using flow cytometry. Knockdown of TDP-43 significantly increased the number of cells stained with PI but not that with stained with Annexin V or TUNEL. *D*, caspase-3/7 activity of Neuro-2a cells transfected with TDP-43 siRNA or control RNA. *E*, time course analysis of neurite outgrowth in Neuro-2a cells transfected with TDP-43 siRNA or control RNA. Averages of the longest neurite lengths of over 100 transfected cells were analyzed 24 h after the transfection of siRNA. Neurites of control cells extended over the course of 48 h, but in TDP-43-depleted cells, neurite outgrowth was inhibited. Error bars indicate S.D. (*A–D*) or S.E. (*E*). *F*, phase-contrast images of Neuro-2a cells 48 h after the transfection of control RNA or TDP-43 siRNA. Scale bar, 10 μ m. N.S., not significant.

Knockdown of TDP-43 Reduces Rho Family GTPase Activity—To elucidate the pathophysiology of neuronal cell death and the morphological alteration caused by TDP-43 depletion, we focused on the Rho family GTPases, which are potent regulators of neurite outgrowth and cell survival. First RhoA, Rac1, and Cdc42 GTPase activities were investigated by pull-down assays. In TDP-43-depleted cells, the activities of RhoA, Rac1, and Cdc42 GTPase were all decreased compared with the controls (Fig. 3, *A* and *B*). Inactivation of RhoA GTPase was also

confirmed by a significant reduction in the level of the Thr-853 phosphorylation of myosin phosphatase targeting subunit 1, which is exclusively phosphorylated by Rho kinase (28) (Fig. 3*A*). To verify that inactivation of Rho family GTPases leads to neuronal damage, we tested the effects of *C. difficile* toxin B, a pan-inhibitor of Rho family proteins, on differentiated Neuro-2a cells. As a result, this toxin reduced cell viability and inhibited neurite outgrowth (Fig. 3, *C* and *D*).

Small G proteins, including Rho and Ras family members, must be able to localize at the cell membrane to exert their biological functions (29). We thus investigated the intracellular distribution of Rho family proteins to elucidate the mechanism by which TDP-43 regulates their GTPase activity. Western blots showed that the amounts of RhoA, Rac1, and Cdc42, but not H-Ras or Rab5, in the membrane fractions were decreased in the TDP-43 knockdown cells (Fig. 4*A*). The subcellular fraction of Rho GDP dissociation inhibitor, another regulator of Rho activity, was not altered by TDP-43 knockdown (Fig. 4*A*). The siRNA-resistant form of TDP-43 rescued the reduction in the amount of membrane-bound Rho family GTPases (Fig. 4*B*). The fluorescent images also demonstrated that membrane-localized Rac1 was significantly reduced in TDP-43 knockdown cells in comparison with control cells (Fig. 5).

TDP-43 Regulates Rho GTPase Activity via Protein Geranylgeranylation—For membrane localization to occur, members of the Rho family of GTPases have to be catalyzed by transferring GGPP to the C-terminal motif (geranylgeranylation), whereas Ras family members, such

as H-Ras, require farnesyl pyrophosphate. We thus tested two agents that modulate geranylgeranylation of Rho family molecules. GGTI-298, a specific inhibitor of geranylgeranylation, has been shown to increase neural cell death through the inactivation of Rho family GTPases (30, 31). In differentiated Neuro-2a cells, GGTI-298 inhibited neurite outgrowth and reduced cell viability in a dose-dependent manner without any evidence of caspase-3/7 activation (Fig. 6, *A–C*). GGTI-298 also decreased the amount of membrane-




FIGURE 3. Activities of Rho family GTPases in TDP-43-depleted Neuro-2a cells. *A*, pull-down assays of RhoA, Rac1, and Cdc42 and Western blot using anti-phospho-myosin phosphatase targeting subunit 1 (*p-MYPT1*) in Neuro-2a cells transfected with TDP-43 siRNA or control RNA. TDP-43 knockdown significantly reduced Rho family GTPase activity. *B*, densitometric quantifications of three independent experiments. *C*, the viabilities of Neuro-2a cells incubated with the indicated concentrations of *C. difficile* toxin B. *D*, quantitation of neurite outgrowth in Neuro-2a cells incubated with 100 ng/ml toxin B compared with control. Error bars indicate S.D. (*B* and *C*) or S.E. (*D*).

bound Rho GTPases (Fig. 6*D*). In contrast, GGPP, the final substrate of geranylgeranylation, prevented the reduction in the amounts of membrane-bound RhoA, Rac1, and Cdc42 caused by TDP-43 knockdown (Fig. 6*E*). In addition, GGPP restored viability and neurite outgrowth in TDP-43-depleted cells (Fig. 6, *F* and *G*). These findings indicate that impaired geranylgeranylation appears to be the molecular basis of TDP-43 depletion-induced cellular damage. We next examined whether TDP-43 regulates geranylgeranylation of Rho GTPases. Fig. 7, *A–C*, shows that TDP-43 increased the amount of membrane-bound Rho GTPases, augmented neurite outgrowth, and increased cell viability in GGTI-298-treated cells.

Taken together, these observations suggest that TDP-43 regulates the activities of Rho family members through protein geranylgeranylation. We thus investigated the effect of TDP-43 depletion on protein geranylgeranylation using

Dysregulation of Rho Families by TDP-43 Depletion




FIGURE 4. Intracellular distribution of Rho family GTPases in TDP-43 knockdown Neuro-2a cells. *A*, Western blots of subcellular fractions (cytosol, membrane, and nucleus) of Neuro-2a cells transfected with TDP-43 siRNA or control RNA. The amount of Rho family members in the membrane fraction was significantly reduced in TDP-43 knockdown cells. This effect, however, was not observed with H-Ras or Rab5. Moreover the subcellular fraction of Rho GDP dissociation inhibitor (*RhoGDI*) was not altered by TDP-43 depletion. GAPDH and integrin $\beta 1$ were used as a cytosol and membrane marker, respectively. *Cyto*, cytosol fraction; *Mem*, membrane fraction; *Nuc*, nuclear fraction. *B*, the effect of the siRNA-resistant form of TDP-43 (*Mut-TDP-43*) on the intracellular distribution of Rho family GTPases. *Mut-TDP-43* prevented the reduction of membrane-bound Rho family members.




FIGURE 5. Fluorescent images of Neuro-2a cells. Neuro-2a cells co-transfected with EGFP-Rac1, DsRed-TDP-43, and siRNA (TDP-43 siRNA or control RNA) were fixed by 4% paraformaldehyde with 0.1% Triton X-100. Membrane-localized Rac1 was significantly reduced in the TDP-43 depleted cells (arrowhead) compared with the cells that escaped knockdown of TDP-43 (arrow) and with the control RNA-transfected cells. Scale bar, 10 μ m.

[14 C]mevalonic acid (MVA). Incorporation of [14 C]MVA into RhoA or Rac1 was significantly decreased in the TDP-43-depleted Neuro-2a cells (Fig. 8, *A* and *B*), suggesting that the knockdown of TDP-43 inhibits geranylgeranylation of Rho family members. GGTI-298 reduced incorporation of [14 C]MVA into Rac1, further confirming this conclusion (Fig. 8*C*).

Protein geranylgeranylation of the Rho family is regulated by specific enzymes: geranylgeranyltransferase-*I* β and geranylgeranyl pyrophosphate synthase-1, which is responsible for synthesis of GGPP. We therefore investigated the expression levels of these enzymes. However, the knockdown of TDP-43 did not alter the protein expression level of geranylgeranyltransferase-*I* β or geranylgeranyl pyrophosphate synthase-1 (data not shown).

Dysregulation of Rho Families by TDP-43 Depletion




FIGURE 6. The effect of modulation of geranylgeranylation on cell viability. *A*, the viability of Neuro-2a cells incubated with the indicated concentrations of GGTI-298 (*GGTI*). *B*, averages of neurite length in Neuro-2a cells incubated with 20 μ M GGTI-298 compared with control. *C*, caspase-3/7 activity in Neuro-2a cells treated with GGTI-298. *D*, Western blot of the membrane fraction from Neuro-2a cells incubated with 20 μ M GGTI-298 compared with control. *E*, Western blot of the membrane fraction from Neuro-2a cells incubated with 20 μ M GGPP in the presence of TDP-43 siRNA. *F*, measurement of neurite length of Neuro-2a cells incubated with 20 μ M GGPP. The cells were transfected with TDP-43 siRNA or control RNA. *G*, the viability of Neuro-2a cells incubated with the indicated concentrations of GGPP. Error bars indicate S.E. (*A* and *C*) or S.E. (*B* and *F*). *N.S.*, not significant.




FIGURE 7. Effect of TDP-43 in Neuro-2a cells on GGTI-298-induced cellular phenotype. *A*, Western blot of the membrane (*Mem*) fraction of 10 μ M GGTI-298 (*GGTI*)-treated Neuro-2a cells transfected with TDP-43 or mock vector. *B*, neurite length of GGTI-298-treated Neuro-2a cells transfected with DsRed-TDP-43 or mock vector. *C*, the viability of Neuro-2a cells incubated with the indicated concentrations of GGTI-298. Error bars indicate S.E. (*B*) or S.D. (*C*).

DISCUSSION

TDP-43 as a Regulator of Rho Family GTPases—In the present study, we demonstrated that knockdown of TDP-43 inhibits neurite outgrowth and induces cell death in differentiated Neuro-2a cells, suggesting that loss of TDP-43 function plays a causative role in neurodegeneration. To elucidate the molecular mechanisms by which TDP-43 depletion causes neuronal cell damage, we examined the relationship between TDP-43 and Rho family GTPases. Neuronal morphology is determined in large part through the regulation of the cytoskeleton. One of the key regulators of the actin cytoskeleton is the Rho family of GTPases: RhoA, Rac1, and Cdc42 (15–17). Although each Rho

G, the viability of Neuro-2a cells incubated with the indicated concentrations of GGPP. Error bars indicate S.E. (*A* and *C*) or S.E. (*B* and *F*). *N.S.*, not significant.